XNAS
SSKN
Market cap0kUSD
Jul 09, Last price
0.00USD
1D
-100.00%
1Q
-100.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
STRATA Skin Sciences Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.
IPO date
Oct 28, 2005
Employees
114
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||